Arcellx Inc
ACLX
Company Profile
Business description
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Contact
800 Bridge Parkway
RedwoodCA94065
USAT: +1 240 327-0603
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
209
Stocks News & Analysis
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
stocks
Revenue growth on track for undervalued ASX healthcare stock
Near-term cost growth does not change our long-term view.
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,155.80 | 34.00 | 0.37% |
| CAC 40 | 8,279.84 | 34.05 | 0.41% |
| DAX 40 | 23,900.57 | 93.58 | 0.39% |
| Dow JONES (US) | 48,006.41 | 179.39 | -0.37% |
| FTSE 100 | 10,615.89 | 12.41 | 0.12% |
| HKSE | 25,893.54 | 141.14 | 0.55% |
| NASDAQ | 22,924.60 | 102.19 | 0.45% |
| Nikkei 225 | 56,924.11 | 1,028.79 | 1.84% |
| NZX 50 Index | 13,181.44 | 92.37 | -0.70% |
| S&P 500 | 6,828.85 | 4.19 | 0.06% |
| S&P/ASX 200 | 8,960.60 | 36.20 | 0.41% |
| SSE Composite Index | 3,986.22 | 20.05 | 0.51% |